Companies · Other Health Care

BioBehavioral Diagnostics Co

PLYMOUTH MEETING · Other Health Care

Diligence memoA one-page analyst read on BioBehavioral Diagnostics Co — recommendation, valuation, rhythm, risks.
$22.5M
Total raised · real
11
Rounds
0.2×
Latest step-up
Top 16%
Sector rank · raised
Series A
Latest stage · inferred · Mon Feb 25 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

BioBehavioral Diagnostics Co looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.08× the median modeled value of Series A Other Health Care companies in 2013–2015 (187 peers) — value vs value, same stage and era.
Dormant
  • Last raise 13.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

BioBehavioral Diagnostics Co is one of 5376 Other Health Care companies tracked from PLYMOUTH MEETING. By capital raised it ranks in the upper tier (ahead of 85% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2009-06-11 Raised $2.5M (real) Modeled valuation $62M (est)Seed2009Seed · 2009-12-04 Raised $500K (real) Modeled valuation $12M (est)Seed2009Seed · 2010-01-26 Raised $500K (real) Modeled valuation $12M (est)Seed2010Series A · 2010-01-29 Raised $5.6M (real) Modeled valuation $113M (est)Series A2010Series A · 2011-04-15 Raised $300K (real) Modeled valuation $6.1M (est)Series A2011Series A · 2011-05-20 Raised $500K (real) Modeled valuation $10M (est)Series A2011Series A · 2011-09-15 Raised $3.1M (real) Modeled valuation $62M (est)Series A2011Series A · 2012-05-22 Raised $5.2M (real) Modeled valuation $104M (est)Series A2012Series A · 2012-07-09 Raised $1.5M (real) Modeled valuation $29M (est)Series A2012Series A · 2012-07-09 Raised $2.5M (real) Modeled valuation $50M (est)Series A2012Series A · 2013-02-25 Raised $500K (real) Modeled valuation $10M (est)Series A2013Cumulative $23M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.5M · 2009
Seed extension$500K · 2009
Seed extension$500K · 2010
Series A$5.6M · 2010
Series A extension$300K · 2011
Series A extension$500K · 2011
Series A extension$3.1M · 2011
Series A extension$5.2M · 2012
Series A extension$1.5M · 2012
Series A extension$2.5M · 2012
Series A extension$500K · 2013

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$10.1M
Base estimate est.
$641K
Conservative case
$54.9M
Upside case
$2.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $62.0M · 2009-06-112009Seed · modeled $12.4M · 2009-12-04Seed · modeled $12.4M · 2010-01-26Series A · modeled $112.8M · 2010-01-29Series A · modeled $6.1M · 2011-04-15Series A · modeled $10.1M · 2011-05-20Series A · modeled $62.2M · 2011-09-15Series A · modeled $104.1M · 2012-05-22Series A · modeled $29.4M · 2012-07-09Series A · modeled $49.5M · 2012-07-09Series A · modeled $10.1M · 2013-02-252013
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
6.0 yr
Elapsed time used
13.3 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
4 mo
Avg between rounds
$6.1M/yr
Capital velocity
17.1 yr
On record since
2009
First round
11
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 9.3× above median
This company$22.5M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.1× of median
This company$500K
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 0.5× of median
This company$10.1M
Sector median$22.1M

Raised more than 85% of sector peers (real $). Modeled value above 34% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #175 of 187.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)Imagine Health, Inc. · Series A Raised $15.0M · modeled $302.7M (est)Inova Labs, Inc. · Series A Raised $32.6M · modeled $302.7M (est)Spruce Health, Inc. · Series A Raised $15.0M · modeled $302.7M (est)Cephea Valve Technologies, Inc. · Series A Raised $21.2M · modeled $296.8M (est)ClarVista Medical, Inc. · Series A Raised $14.5M · modeled $293.0M (est)Minimally Invasive Devices Inc. · Series A Raised $43.3M · modeled $284.9M (est)Osprey Medical Inc. · Series A Raised $14.0M · modeled $282.5M (est)IGeneX Group, LLC · Series A Raised $13.5M · modeled $273.4M (est)Urohsd, Llc · Series A Raised $13.2M · modeled $266.9M (est)Secure EDI Holdings, LLC · Series A Raised $28.3M · modeled $263.5M (est)Sterling Healthcare Holdings, Llc · Series A Raised $13.4M · modeled $259.1M (est)Wallick Senior Housing Holdings, LLC · Series A Raised $12.8M · modeled $259.1M (est)BioBehavioral Diagnostics Co (this company) Raised $22.5M · modeled $10.1M (est)BioBehavioral Diagnostics Co
CompanyStageRaised · realValue · estvs peer med.
Imagine Health, Inc.Series A$15.0M$302.7M2.50×
Inova Labs, Inc.Series A$32.6M$302.7M2.50×
Spruce Health, Inc.Series A$15.0M$302.7M2.50×
Cephea Valve Technologies, Inc.Series A$21.2M$296.8M2.46×
ClarVista Medical, Inc.Series A$14.5M$293.0M2.42×
Minimally Invasive Devices Inc.Series A$43.3M$284.9M2.36×
Osprey Medical Inc.Series A$14.0M$282.5M2.34×
IGeneX Group, LLCSeries A$13.5M$273.4M2.26×
Urohsd, LlcSeries A$13.2M$266.9M2.21×
Secure EDI Holdings, LLCSeries A$28.3M$263.5M2.18×
Sterling Healthcare Holdings, LlcSeries A$13.4M$259.1M2.14×
Wallick Senior Housing Holdings, LLCSeries A$12.8M$259.1M2.14×
BioBehavioral Diagnostics Co this companySeries A$22.5M$10.1M0.08×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.5M2009-06-11$12.5M$62.0M90%
Seed$500K2009-12-04$2.5M$12.4M90%
Seed$500K2010-01-26$2.5M$12.4M90%
Series A$5.6M2010-01-29$25.4M$112.8M90%
Series A$300K2011-04-15$1.4M$6.1M90%
Series A$500K2011-05-20$2.3M$10.1M90%
Series A$3.1M2011-09-15$14.0M$62.2M90%
Series A$5.2M2012-05-22$23.5M$104.1M90%
Series A$1.5M2012-07-09$6.6M$29.4M90%
Series A$2.5M2012-07-09$11.2M$49.5M90%
Series A$500K2013-02-25$2.3M$10.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.5M2009-06-11
    • First recorded raise — entered as Seed.
  2. Seed$500K2009-12-04
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 5.0× smaller than the prior — bridge or down round.
  3. Seed$500K2010-01-26
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  4. Series A$5.6M2010-01-29
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 11.2× larger than the prior — scaling up.
  5. Series A$300K2011-04-15
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 18.6× smaller than the prior — bridge or down round.
  6. Series A$500K2011-05-20
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
  7. Series A$3.1M2011-09-15
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 6.2× larger than the prior — scaling up.
  8. Series A$5.2M2012-05-22
    • Raised 8 mo later, in step with the ~14 mo sector norm.
    • Round 1.7× larger than the prior — scaling up.
  9. Series A$1.5M2012-07-09
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 3.5× smaller than the prior — bridge or down round.
  10. Series A$2.5M2012-07-09
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× larger than the prior — scaling up.
  11. Series A$500K2013-02-25
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 4.9× smaller than the prior — bridge or down round.
Intelligence
2013 ~Q3
Modeled next raise · ~4mo cadence
$500K
Modeled next size est.range $500K$800K
0.2×
Last step-up
$6.1M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Byron Hewett2 other2009-06
John V. Jaggers2 other2013-02
David J. McLean1 other2009-06
Eric B. Gordon1 other2009-06
Peter A. Paskevich2009-06
Sandford J. Smith2009-12
Teresa J. Lipcsey2011-04
Registry & provenance

BioBehavioral Diagnostics Co is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1386204
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
YouDocs Beauty, Inc.Other Health CareSeries A$23.7M$8.6Msame sector · same stage
Qliance Medical Management Inc.Other Health CareSeries A$20.9M$9.1Msame sector · same stage
Somatix, Inc.Other Health CareSeries A$20.8M$8.1Msame sector · same stage
Medbox, Inc.Other Health CareSeries A$26.4M$8.1Msame sector · same stage
iOR Holdings, Inc.Other Health CareSeries A$18.0M$8.7Msame sector · same stage
Perfusio Corp.Other Health CareSeries A$16.4M$9.3Msame sector · same stage
SentiAR, Inc.Other Health CareSeries A$15.2M$8.8Msame sector · same stage
Mirabilis Medica, Inc.Other Health CareSeries A$33.7M$8.7Msame sector · same stage
Frequently asked
How much funding has BioBehavioral Diagnostics Co raised?
BioBehavioral Diagnostics Co has raised approximately $22.5M in disclosed capital across 11 recorded financing rounds, aggregated from public filings.
What is BioBehavioral Diagnostics Co's estimated valuation?
Provath's modeled valuation for BioBehavioral Diagnostics Co is approximately $10.1M (modeled range $641K–$54.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is BioBehavioral Diagnostics Co at?
BioBehavioral Diagnostics Co's latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Feb 25.
What does BioBehavioral Diagnostics Co do and where is it based?
BioBehavioral Diagnostics Co operates in the Other Health Care sector, based in PLYMOUTH MEETING.
Explore related

See where BioBehavioral Diagnostics Co sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at BioBehavioral Diagnostics Co, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.